These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29279487)

  • 1. Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03).
    Yamamoto-Honda R; Takahashi Y; Mori Y; Yamashita S; Yoshida Y; Kawazu S; Iwamoto Y; Kajio H; Yanai H; Mishima S; Handa N; Shimokawa K; Yoshida A; Watanabe H; Ohe K; Shimbo T; Noda M
    Intern Med; 2018 May; 57(9):1229-1240. PubMed ID: 29279487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
    Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
    Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42).
    Fujihara K; Igarashi R; Matsunaga S; Matsubayashi Y; Yamada T; Yokoyama H; Tanaka S; Shimano H; Maegawa H; Yamazaki K; Kawai K; Sone H
    Medicine (Baltimore); 2017 Feb; 96(7):e6122. PubMed ID: 28207538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
    Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
    Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
    Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
    Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.
    Heintjes EM; Overbeek JA; Hall GC; Prieto-Alhambra D; Lapi F; Hammar N; Bezemer ID
    Clin Ther; 2017 Nov; 39(11):2296-2310.e14. PubMed ID: 29108837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
    Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
    JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in medication utilization, glycemic control and outcomes among type 2 diabetes patients in a tertiary referral center in Singapore from 2007 to 2017.
    Tan YZ; Cheen MHH; Goh SY; Bee YM; Lim PS; Khee GY; Thumboo J
    J Diabetes; 2019 Jul; 11(7):573-581. PubMed ID: 30556375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Glucose-Lowering Drug Use, Glycemic Control, and Severe Hypoglycemia in Adults With Diabetes in Hong Kong, 2002-2016.
    Yang A; Wu H; Lau ESH; Ma RCW; Kong APS; So WY; Luk AOY; Chan JCN; Chow E
    Diabetes Care; 2020 Dec; 43(12):2967-2974. PubMed ID: 33046501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea.
    Omori K; Nomoto H; Nakamura A; Takase T; Cho KY; Ono K; Manda N; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    J Diabetes Investig; 2019 Mar; 10(2):367-374. PubMed ID: 29963781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013.
    Lipska KJ; Yao X; Herrin J; McCoy RG; Ross JS; Steinman MA; Inzucchi SE; Gill TM; Krumholz HM; Shah ND
    Diabetes Care; 2017 Apr; 40(4):468-475. PubMed ID: 27659408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
    Katsuno T; Ikeda H; Ida K; Miyagawa J; Namba M
    Endocr J; 2013; 60(6):733-42. PubMed ID: 23386390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
    Hayashi T; Murayama H; Shinfuku Y; Taniguchi T; Tsumiyama I; Oyama N
    Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
    Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND).
    Tajima A; Tobe K; Eiki JI; Origasa H; Watada H; Shimomura I; Tokita S; Kadowaki T
    BMJ Open Diabetes Res Care; 2022 Dec; 10(6):. PubMed ID: 36585033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH; Feng ZK; Xu LH
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
    [No Abstract]   [Full Text] [Related]  

  • 20. Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.
    Mahmoud F; Mullen A; Sainsbury C; Rushworth GF; Yasin H; Abutheraa N; Mueller T; Kurdi A
    Eur J Clin Invest; 2023 Aug; 53(8):e13997. PubMed ID: 37002856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.